TILT Holdings (TLLTF) Total Non-Current Liabilities (2021 - 2025)
TILT Holdings (TLLTF) reported Total Non-Current Liabilities of $200.6 million for Q2 2025, up 16.41% on a YoY basis from $172.3 million in Q2 2024, and little changed quarter-over-quarter from $199.9 million in Q1 2025.
TILT Holdings (TLLTF) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
TILT Holdings has reported Total Non-Current Liabilities for 5 years, with the latest figure at $200.6 million in Q2 2025.
- For the quarter ending Q2 2025, Total Non-Current Liabilities rose 16.41% year-over-year to $200.6 million; the trailing twelve-month figure through Jun 2025 stood at $200.6 million (up 16.41% YoY), and the FY2024 full-year result was $188.2 million, up 12.19% from the prior year.
- Total Non-Current Liabilities for Q2 2025 stood at $200.6 million, roughly flat from $199.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $200.6 million in Q2 2025, with the low at $153.3 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $176.4 million across 5 years, with a median of $172.2 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities decreased 13.63% — and 2025, when it advanced 16.41%.
- TILT Holdings' Total Non-Current Liabilities stood at $153.3 million in 2021, then advanced by 12.33% to $172.2 million in 2022, then dropped by 2.58% to $167.7 million in 2023, then gained by 12.19% to $188.2 million in 2024, then gained by 6.58% to $200.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $200.6 million (Q2 2025), $199.9 million (Q1 2025), and $188.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | TILT Holdings | - | - | 1.82 Mn | 200.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 200.56 Mn |
| Mar 31, 2025 | 199.95 Mn |
| Dec 31, 2024 | 188.18 Mn |
| Sep 30, 2024 | 177.66 Mn |
| Jun 30, 2024 | 172.29 Mn |
| Mar 31, 2024 | 178.10 Mn |
| Dec 31, 2023 | 167.74 Mn |
| Sep 30, 2023 | 165.86 Mn |
| Jun 30, 2023 | 165.46 Mn |
| Mar 31, 2023 | 166.04 Mn |
| Dec 31, 2022 | 172.19 Mn |
| Sep 30, 2022 | 170.53 Mn |
| Jun 30, 2022 | 191.56 Mn |
| Dec 31, 2021 | 153.29 Mn |